The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin
| Autor: | Nellowe Candelario, Jedrzej Wykretowicz |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Pediatrics Diabetic ketoacidosis medicine.medical_treatment Case Report 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology Microbiology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Diabetes mellitus medicine Empagliflozin Dapagliflozin Intensive care medicine Canagliflozin business.industry Insulin medicine.disease Ketoacidosis Infectious Diseases chemistry Parasitology business medicine.drug |
| Zdroj: | Oxford Medical Case Reports |
| ISSN: | 2053-8855 |
| DOI: | 10.1093/omcr/omw061 |
| Popis: | Sodium glucose co-transporter (SGLT-2) inhibitor is a relatively new medication used to treat diabetes. At present, the Food and Drug Administration (FDA) has only approved three medications (canagliflozin, dapagliflozin and empagliflozin) in this drug class for the management of Type 2 diabetes. In May 2015, the FDA issued a warning of ketoacidosis with use of this drug class. Risk factors for the development of ketoacidosis among patients who take SGLT-2 inhibitors include decrease carbohydrate intake/starvation, acute illness and decrease in insulin dose. When identified, immediate cessation of the medication and administration of glucose must be done, and in some instances, starting an insulin drip might be necessary. We present a case of a patient with diabetes mellitus being on empagliflozin (SGLT-2 antagonist) who was admitted for acute cholecystitis. The hospital course was complicated by euglycemic diabetic ketoacidosis after being kept nothing per orem before a contemplated cholecystectomy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|